Study to Evaluate the Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma
Active, not recruiting
Kite, A Gilead Company
Phase 2
2015-11-09
The primary objective of the study is to evaluate the efficacy of brexucabtagene autoleucel
(KTE-X19) in participants with relapsed/refractory mantle cell lymphoma (MCL)
A Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3)
Active, not recruiting
Kite, A Gilead Company
Phase 1/Phase 2
2016-03-07
The primary objectives of this study are to determine the safety and efficacy of
brexucabtagene autoleucel (KTE-X19) adult participants with relapsed/refractory (r/r)
B-precursor acute lymphoblastic leukemia (ALL).
Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Recruiting
Kite, A Gilead Company
Phase 1/Phase 2
2016-02-01
The primary objectives of this study are to evaluate the safety and efficacy of
brexucabtagene autoleucel (KTE-X19) in pediatric and adolescent participants with
relapsed/refractory (r/r) B-precursor acute lymphoblastic leukemia (ALL) or relapsed or
refractory (r/r) B-cell non-Hodgkin lymphoma (NHL).
Safety and Tolerability of Brexucabtagene Autoleucel (KTE-X19) in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Active, not recruiting
Kite, A Gilead Company
Phase 1
2018-11-15
The primary objective of this study is to evaluate the safety and tolerability of
brexucabtagene autoleucel (KTE-X19) in adults with relapsed/refractory chronic lymphocytic
leukemia (r/r CLL) and small lymphocytic lymphoma (r/r SLL).
MT2017-45: CAR-T Cell Therapy for Heme Malignancies
Recruiting
Masonic Cancer Center, University of Minnesota
2018-12-18
This is a phase II study of FDA-approved CAR-T products for patients with hematologic
malignancies. Patients will be assigned to Arm A and B based on age and diagnosis. Overall
remission rate, safety events and other endpoints will be calculated for Arm A and B
separately.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
